BridgeBio Pharma Inc

BBIO: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
vnLOCK|CZLOCK|K>PY&c

BridgeBio: Positive BBP-418 Phase 3 Results Advance Another Win for BridgeBio's Portfolio

BridgeBio shares surged nearly 20% on Oct. 27 after the company announced positive phase 3 results for its small-molecule candidate BBP-418 in limb-girdle muscular dystrophy type 2I/R9, with the trial meeting all primary and secondary interim endpoints.

Sponsor Center